Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07071051 · ClinicalTrials.gov registry record

Exploring the Effect of Calaspargase Pegol on the Coagulation System in Pediatric Acute Lymphoblastic Leukemia (ALL) Patients: Pilot Study

A clinical trial of Childhood Acute Lymphoblastic Leukemia and Childhood Lymphoblastic Lymphoma, sponsored by Mayo Clinic.

Recruiting
Registry status
15
Enrollment target
1
Study location

NCT07071051 is a study of Childhood Acute Lymphoblastic Leukemia and Childhood Lymphoblastic Lymphoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 15 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07071051, a study of Childhood Acute Lymphoblastic Leukemia and Childhood Lymphoblastic Lymphoma, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
15 participants
Enrollment target
1
Study location

Study Summary

This study evaluates the impact of calaspargase pegol (Cal-PEG) on the coagulation system in pediatric patients with acute lymphoblastic leukemia/lymphoma (ALL).

Interventions

  • OTHER Non-Interventional Study

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2025-07-31
Est. Completion 2026-12-31

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT07071051

The ClinicalTrials.gov registry entry for NCT07071051 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Childhood Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Non-Interventional Study is the first listed.

NCT07071051 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT07071051 about?

NCT07071051 is a clinical study titled "Exploring the Effect of Calaspargase Pegol on the Coagulation System in Pediatric Acute Lymphoblastic Leukemia (ALL) Patients: Pilot Study". This study evaluates the impact of calaspargase pegol (Cal-PEG) on the coagulation system in pediatric patients with acute lymphoblastic leukemia/lymphoma (ALL).

What is the current status of trial NCT07071051?

This trial is currently recruiting. The enrollment target is 15 participants. The study started on 2025-07-31. Estimated completion is 2026-12-31.

What conditions does trial NCT07071051 study?

This clinical trial studies the following conditions: Childhood Acute Lymphoblastic Leukemia, Childhood Lymphoblastic Lymphoma.

What interventions are being tested in trial NCT07071051?

The interventions under investigation include: Non-Interventional Study (OTHER).

Who is sponsoring clinical trial NCT07071051?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07071051 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Childhood Acute Lymphoblastic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.